Helicase-based rapid DNA diagnostic for Biodefense

Award Information
Agency:
Department of Health and Human Services
Amount:
$934,198.00
Program:
SBIR
Contract:
1R43AI066487-01
Solitcitation Year:
2005
Solicitation Number:
PHS2005-2
Branch:
N/A
Award Year:
2005
Phase:
Phase I
Agency Tracking Number:
AI066487
Solicitation Topic Code:
N/A
Small Business Information
BIOHELIX CORPORATION
Biohelix Corporation, 32 Tozer Rd, Beverly, MA, 01915
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 HUIMIN KONG
 (978) 998-7285
 kong@biohelix.com
Business Contact
Phone: (978) 927-5054
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Nucleic acid based diagnostic devices allow accurate identification of biological agents by specifically amplifying specific target sequences from environmental samples. Current diagnostic tests rely on PCR, a more costly and time-consuming detection method that cannot be easily adapted for use in the field. An inexpensive, easy-to-use hand-held diagnostic test for the detection of biological agents onsite will allow first responders to rapidly assess a potential bioterrorism threat. Our laboratory has developed an isothermal DNA amplification system that can be performed independently of a thermal cycler. The technology, Helicase-Dependent Amplification (HDA), employs helicase to enzymatically unwind DNA, rather than using high temperature, to expose the target sequence and allow specific primers to anneal, followed by DNA polymerase mediated primer extension. Products from each cycle of HDA enter the next cycle, resulting in exponential amplification. The technology has been demonstrated to detect as little as 100 cells of the bioterrorism agent Bacillus anthracis. With continued research, the sensitivity and efficiency of HDA will be improved upon and used in the next generation of isothermal nucleic acid diagnostic tests. The main objective of the Phase I research is to innovate HDA by determining and addressing the limitations of the HDA platform and to develop a reverse transcription HDA (RT-HDA) system for use in a multiplexed test for the simultaneous detection of DNA and RNA encoded pathogens, such as B. anthracis and Ebola virus. The aims of Phase I will examine devising an efficient primer design protocol, improving HDA by enhancing the performance of HDA enzymes and developing a one-step, isothermal RT-HDA platform. Innovations to the HDA technology in Phase I will allow the development and production of hand-held HDA based diagnostic devices in Phase II. By innovating the quality of diagnostic testing, we seek to provide emergency personnel with the necessary tools to protect communities from potential biological threats.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government